Opioid REceptors on Lymphocytes and Brain
淋巴细胞和大脑上的阿片受体
基本信息
- 批准号:7173433
- 负责人:
- 金额:$ 11.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-02-01 至 2008-01-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgonistAmino Acid Sequence HomologyAntibodiesAwardBindingBrainCD8B1 geneCell CycleCell surfaceCellsCocaineCocaine AbuseCollaborationsDopamineDrug abuseEducational process of instructingEnsureFentanylFlow CytometryFluoresceinFluoresceinsGoalsGrantHeroinHeroin AbuseHerpesviridaeHumanImmuneInterphase CellLabelLigandsLocalizedLymphocyteLymphocyte ActivationMentorsMethodsMorphine Derivatives Including CocaineMusNational Institute of Drug AbuseNucleus AccumbensOpioidOpioid ReceptorPeritoneal MacrophagesPharmaceutical PreparationsPhycoerythrinPopulationPostdoctoral FellowProceduresProductivityPropertyReceptor ActivationReceptor CellRegulationRelative (related person)ResearchResearch ActivityResearch PersonnelResearch TrainingSelf AdministrationSenior ScientistSenior Scientist AwardSignal TransductionStaining and LabelingStreptavidinStudentsT-Cell ReceptorT-LymphocyteTestingTimeTrainingTraining ActivityWagesWorkWritingchemokinechemokine receptordrug seeking behaviorkappa opioid receptorsmacrophagemu opioid receptorsnaltrindolenext generationnonhuman primatenovelpreventreceptorreceptor expressionresearch studytherapy developmentthymocyte
项目摘要
DESCRIPTION (provided by applicant):
This K05 Senior Scientist Award is to support Dr. Jean M. Bidlack's research activities. The specific aim of this award is to provide Dr. Bidlack with some release time from grant writing, teaching and administrative responsibilities to cover her salary. This award will allow her to devote the majority of her time to research and the training of graduate students and postdoctoral fellows. Training activities will be supported by a NIDA Training Grant (T32 DA07232). Dr. Bidlack will expand her research background and expertise in studying the expression and regulation of opioid receptors on immune cells. Also, she will investigate whether a chemokine receptor expressed on human herpes virus -6 and -7 binds opioids, and if opioids alter chemokine activation of the receptor. This chemokine receptor, U51, shares considerable amino acid sequence homology and similarity with the kappa opioid receptor. In addition, ongoing studies directed at medications development for the treatment of heroin and cocaine abuse will continue. The working hypothesis for which we have produced experimental support is that compounds, which release dopamine from the nucleus accumbens, promote drug-seeking behavior and those, which prevent release of this transmitter, prevent drug-seeking behavior. It is known that kappa agonists and mu antagonists inhibit dopamine release in the nucleus accumbens. Studies are further defining properties of select compounds that make some ? agonists with varying activity at mu receptors better at reducing cocaine self-administration in nonhuman primates than other compounds. In collaboration with chemists and behaviorists, we are evaluated new opioids as potential pharmacotherapeutics for treating drug abuse. The goals of these three independent projects will be accomplished within the framework of two R01 grants, a R21 grant, and three subcontracts from NIDA. Collectively, these projects will provide new information on the localization and function of the multiple opioid receptors on immune cells and on the human herpes viruses -6 and -7. Also, they will advance efforts in developing drugs to treat cocaine and heroin abuse. The present proposal is being requested in order to provide the candidate with stability of support, which is necessary for her continued commitment to research in the field of drug abuse and to ensure her sustained high level of productivity as both a senior scientist, and as a mentor for trainees, who will be the next generation of drug abuse researchers.
描述(由申请人提供):
K 05高级科学家奖旨在支持Jean M. Bidlack的研究活动。该奖项的具体目的是为比德莱克博士提供一些从赠款写作,教学和行政责任中解脱出来的时间,以支付她的工资。该奖项将使她能够将大部分时间用于研究和研究生和博士后研究员的培训。培训活动将得到NIDA培训补助金(T32 DA 07232)的支持。Bidlack博士将扩大她在研究免疫细胞上阿片受体的表达和调节方面的研究背景和专业知识。此外,她还将研究人类疱疹病毒-6和-7上表达的趋化因子受体是否与阿片类药物结合,以及阿片类药物是否会改变趋化因子对受体的激活。这种趋化因子受体U 51与κ阿片受体具有相当大的氨基酸序列同源性和相似性。此外,将继续进行针对开发治疗海洛因和可卡因滥用的药物的研究。我们已经得到实验支持的工作假设是,从脑桥核释放多巴胺的化合物会促进觅药行为,而那些阻止这种递质释放的化合物会阻止觅药行为。已知κ激动剂和μ拮抗剂抑制丘脑核中的多巴胺释放。研究正在进一步确定选择的化合物的性质,使一些?对μ受体具有不同活性的激动剂在减少非人灵长类动物中可卡因自我给药方面比其它化合物更好。与化学家和行为学家合作,我们评估了新的阿片类药物作为治疗药物滥用的潜在药物治疗剂。这三个独立项目的目标将在两个R 01赠款,一个R21赠款和NIDA的三个分包合同的框架内完成。总的来说,这些项目将提供关于免疫细胞和人类疱疹病毒-6和-7上多种阿片受体的定位和功能的新信息。此外,他们还将推动开发治疗可卡因和海洛因滥用的药物的努力。请求提出本建议是为了向候选人提供稳定的支助,这是她继续致力于药物滥用领域的研究所必需的,并确保她作为一名资深科学家和作为将成为下一代药物滥用研究人员的受训人员的导师保持高水平的生产力。
项目成果
期刊论文数量(38)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Synthesis and pharmacology of 8-amino-3-[(tetrahydro-2-furanyl)methyl] benzomorphan.
8-氨基-3-[(四氢-2-呋喃基)甲基]苯并吗喃的合成和药理学。
- DOI:
- 发表时间:2003
- 期刊:
- 影响因子:0
- 作者:Zhou,Qun;Duan,Wen-hu;Cohen,DanaJ;Bidlack,JeanM;Wentland,MarkP
- 通讯作者:Wentland,MarkP
Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol.
6,7-吲哚/噻唑吗啡喃的合成和药理评价——左啡诺的进一步SAR。
- DOI:10.1021/jm0701674
- 发表时间:2007
- 期刊:
- 影响因子:7.3
- 作者:Zhang,Ao;Li,Fuying;Ding,Chunyong;Yao,Qizhen;Knapp,BrianI;Bidlack,JeanM;Neumeyer,JohnL
- 通讯作者:Neumeyer,JohnL
Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism.
- DOI:10.1016/j.seizure.2008.06.014
- 发表时间:2009-01
- 期刊:
- 影响因子:3
- 作者:Bidlack, Jean M.;Morris, Harold H., III
- 通讯作者:Morris, Harold H., III
Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines.
- DOI:10.1021/jm020429w
- 发表时间:2003-02
- 期刊:
- 影响因子:7.3
- 作者:M. Wentland;Y. Ye;C. Cioffi;R. Lou;Qun Zhou;Guoyou Xu;W. Duan;C. Dehnhardt;Xufeng Sun;D. J. Cohen;J. Bidlack
- 通讯作者:M. Wentland;Y. Ye;C. Cioffi;R. Lou;Qun Zhou;Guoyou Xu;W. Duan;C. Dehnhardt;Xufeng Sun;D. J. Cohen;J. Bidlack
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
- DOI:10.1016/j.bmcl.2008.10.134
- 发表时间:2009
- 期刊:
- 影响因子:2.7
- 作者:M. Wentland;R. Lou;Qun Lu;Yigong Bu;Melissa A. VanAlstine;D. J. Cohen;J. Bidlack
- 通讯作者:M. Wentland;R. Lou;Qun Lu;Yigong Bu;Melissa A. VanAlstine;D. J. Cohen;J. Bidlack
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEAN M BIDLACK其他文献
JEAN M BIDLACK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEAN M BIDLACK', 18)}}的其他基金
G alpha Z subunit as a potential therapeutic target to modulate mu opioid receptor pharmacology
G α Z 亚基作为调节 mu 阿片受体药理学的潜在治疗靶点
- 批准号:
10580415 - 财政年份:2022
- 资助金额:
$ 11.93万 - 项目类别:
38th Annual International Narcotics Research Conference
第 38 届国际麻醉品研究年度会议
- 批准号:
7334676 - 财政年份:2007
- 资助金额:
$ 11.93万 - 项目类别:
37th Annual International Narcotics Research Conference
第 37 届国际麻醉品研究年度会议
- 批准号:
7167690 - 财政年份:2006
- 资助金额:
$ 11.93万 - 项目类别:
36th Annual International Narcotics Research Conference
第 36 届国际麻醉品研究年度会议
- 批准号:
7005344 - 财政年份:2005
- 资助金额:
$ 11.93万 - 项目类别:
Opioid Binding to U51: A Human herpes Virus Protein
阿片类药物与 U51 结合:人类疱疹病毒蛋白
- 批准号:
6447741 - 财政年份:2001
- 资助金额:
$ 11.93万 - 项目类别:
Opioid Binding to U51: A Human herpes Virus Protein
阿片类药物与 U51 结合:人类疱疹病毒蛋白
- 批准号:
6523577 - 财政年份:2001
- 资助金额:
$ 11.93万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 11.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 11.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)